Cargando…
Kynurenine pathway of tryptophan metabolism in pathophysiology and therapy of major depressive disorder
Serotonin deficiency in major depressive disorder (MDD) has formed the basis of antidepressant drug development and was originally attributed to induction of the major tryptophan (Trp)-degrading enzyme, liver Trp 2,3-dioxygenase (TDO), by cortisol, leading to decreased Trp availability to the brain...
Autores principales: | Badawy, Abdulla A-B, Dawood, Shazia, Bano, Samina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10130957/ https://www.ncbi.nlm.nih.gov/pubmed/37123095 http://dx.doi.org/10.5498/wjp.v13.i4.141 |
Ejemplares similares
-
Tryptophan Metabolism in Rat Liver After Administration of Tryptophan, Kynurenine Metabolites, and Kynureninase Inhibitors
por: Badawy, Abdulla A.-B., et al.
Publicado: (2016) -
Inflammation and serotonin deficiency in major depressive disorder: molecular docking of antidepressant and anti-inflammatory drugs to tryptophan and indoleamine 2,3-dioxygenases
por: Dawood, Shazia, et al.
Publicado: (2022) -
The kynurenine pathway of tryptophan metabolism: a neglected therapeutic target of COVID-19 pathophysiology and immunotherapy
por: Badawy, Abdulla Abu-Bakr
Publicado: (2023) -
Kynurenine Pathway of Tryptophan Metabolism: Regulatory and Functional Aspects
por: Badawy, Abdulla A-B
Publicado: (2017) -
Kynurenine Pathway of Tryptophan Metabolism in Neuropsychiatric Disorders: Pathophysiologic and Therapeutic Considerations
por: Muneer, Ather
Publicado: (2020)